afr, page-15

D,

You are wasting your time; he only knows one thing and that Nexavar, Nexavar, Nexavar.......

As you know Post resection liver is only 25% (Nexavar are the over 75%) of the total liver cancer market and if PGL can capture 10% of that there SP is many multiplies of what it is today. With 677,000 cases of liver cancer world wide and 60% of those being in countries that can afford treatment and 25% of those eligible for resection give a number around 100,000 accessible patients world wide.

Drugs like Avastin and Nexavar sell for around $40,000 US for a year’s treatment, at 10,000 sales a year that around $400 million US. If you put half that on a multiple of 7 times earning and divided it by 60million shares it give you some idea of the value of this compound.

Today’s announcement signals the start of the trial that will give us the answer we are seeking. IMO today’s SP has very little down side and a considerable up side. Be that by either a Buy Out in the short term or positive trail results in the medium term. This trail will be a lot shorter than many expect, remember this is what the Hat does best, and he knows the process inside out.

PA